Molnupiravir is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine. It exerts its antiviral action through introduction of copying errors during viral RNA replication. Activity has been demonstrated against coronaviruses including SARS, MERS and SARS-CoV-2.
About Molnupiravir in brief
Molnupiravir is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine. It exerts its antiviral action through introduction of copying errors during viral RNA replication. Activity has also been demonstrated against coronaviruses including SARS, MERS and SARS-CoV-2.
The drug was developed at Emory University by the university’s drug innovation company, Drug Innovation Ventures. It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck &
You want to know more about Molnupiravir?
This page is based on the article Molnupiravir published in Wikipedia (as of Dec. 07, 2020) and was automatically summarized using artificial intelligence.
